- Previous Close
0.0430 - Open
0.0420 - Bid 0.0410 x --
- Ask 0.0420 x --
- Day's Range
0.0420 - 0.0420 - 52 Week Range
0.0370 - 0.0660 - Volume
368,631 - Avg. Volume
449,721 - Market Cap (intraday)
36.97M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
ptxtherapeutics.comRecent News: PTX.AX
View MorePerformance Overview: PTX.AX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTX.AX
View MoreValuation Measures
Market Cap
34.63M
Enterprise Value
26.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-233.95%
Return on Assets (ttm)
-17.58%
Return on Equity (ttm)
-36.95%
Revenue (ttm)
3.02M
Net Income Avi to Common (ttm)
-7.07M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
8.41M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
-8.29M